| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:CWI1-2
CAS:2408590-36-1
Purity:98% Package:100mg Remarks:S34012
|
| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:CWI1-2
CAS:2408590-36-1
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Zhengzhou convergence chemical co., LTD
|
| Tel: |
0371-0371-55153829 18003835034 |
| Email: |
2853979819@qq.com |
| Products Intro: |
Product Name:N',N'',2-Tris(5-chloro-2-hydroxybenzylidene)hydrazine-1-carbohydrazonhydrazide , CWI1-2
CAS:2408590-36-1
Purity:98% Package:100mg 250mg 500mg 1g 2g 5g 10g 25g 50g 100g 250g 500g 1kg
|
|
| Product Name: | CWI1-2 | | Synonyms: | CWI1-2;NND-2341703;N',N'',2-Tris(5-chloro-2-hydroxybenzylidene)hydrazine-1-carbohydrazonhydrazide , CWI1-2;N',N'',2-Tris(5-chloro-2-hydroxybenzylidene)hydrazine-1-carbohydrazonhydrazide;N',N'',2-Tris(5-chloro-2-hydroxybenzylidene)hydrazine-1-carbohydrazonhydrazide | | CAS: | 2408590-36-1 | | MF: | C22H17Cl3N6O3 | | MW: | 519.77 | | EINECS: | | | Product Categories: | | | Mol File: | 2408590-36-1.mol |  |
| | CWI1-2 Chemical Properties |
| Boiling point | 711.029±70.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.490±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | form | Solid | | pka | 7.895±0.48(predicted) | | color | Light yellow to yellow |
| | CWI1-2 Usage And Synthesis |
| Uses | CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects[1]. | | in vivo | CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight[1].
| | References | [1] Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. DOI:10.1016/j.ccell.2022.10.004 |
| | CWI1-2 Preparation Products And Raw materials |
|